NCT01647555 2026-03-18
Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer
Centre Oscar Lambret
Completed
Clinical Trials
14 trialsNCT01827956 2025-12-29
FCR-VADS
Institut Bergonié
Completed
NCT07015333 2025-06-11
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Commonwealth Healthcare Corporation
Completed
NCT03914170 2023-09-26
ESTER
Institut du Cancer de Montpellier - Val d'Aurelle
Completed
NCT04672772 2022-03-23
Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Completed
NCT01310985 2019-03-01
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
King Faisal Specialist Hospital & Research Center
Completed
NCT01466257 2017-05-19
Biomarkers in Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Completed
NCT01466244 2017-05-17
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
Eastern Cooperative Oncology Group
Completed
NCT01382407 2017-04-27
Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab
Rambam Health Care Campus
Completed
NCT02994888 2016-12-19
PROSPECT-C
Royal Marsden NHS Foundation Trust
Completed
NCT01075828 2014-08-29
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Merck KGaA, Darmstadt, Germany
Completed
NCT01082315 2014-08-29
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Completed
NCT01080066 2014-07-08
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
Merck KGaA, Darmstadt, Germany
Completed
NCT00912327 2012-02-15
Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer
HiberCell, Inc.
Completed